Physician profile
Robin Suzanne Brown
NPI 1801445903
$4,631.44
in general payments reported to CMS, 2019-2025
25 companies · $1,837 in 2025
The $1,837 reported for 2025 was more than what 93% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.37 · 2022: $791 · 2023: $1,191 · 2024: $749 · 2025: $1,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,893 · Travel and Lodging: $826 · Education: $57.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,893.12 |
| Travel and Lodging | $825.84 |
| Education | $57.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,402.81 | 2023-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $522.27 | 2022-2025 | Verquvo, Capvaxive |
| Regeneron Healthcare Solutions, INC. | $435.80 | 2022-2023 | Dupixent |
| Boston Scientific Corporation | $410.92 | 2022-2025 | Watchman Flx, Watchman Access System, Farapulse |
| Novartis Pharmaceuticals Corporation | $276.68 | 2021-2025 | |
| Pfizer INC. | $233.39 | 2022-2025 | |
| Amgen INC. | $138.61 | 2022-2024 | Repatha |
| Impulse Dynamics (USA) INC. | $136.51 | 2022-2025 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $130.78 | 2022-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $127.27 | 2021-2023 | Uptravi, Opsumit |
| Lexicon Pharmaceuticals, INC. | $118.97 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $118.95 | 2023-2025 | Farxiga, Wainua |
| Novo Nordisk INC | $102.65 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $67.71 | 2022-2023 | Injectafer |
| Csl Behring | $63.77 | 2024 | Haegarda |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.71 | 2021-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.80 | 2023 | Jardiance |
| Edwards Lifesciences Corporation | $51.52 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| United Therapeutics Corporation | $51.52 | 2022-2024 | Remodulin, Orenitram |
| Bridgebio Pharma, INC. | $45.74 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $24.41 | 2024 | Amvuttra |
| Scpharmaceuticals INC. | $16.50 | 2025 | |
| Baxter Healthcare | $15.23 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $15.12 | 2022 | |
| Kestra Medical Technology Services, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.